GlaxoSmithKline and Vir Biotech seek FDA emergency authorization for COVID antibody treatmentMarket Watch • 03/26/21
GSK and Vir Biotechnology Announce Submission of Emergency Use Authorization Request to FDA for VIR-7831 for the Early Treatment of COVID-19GlobeNewsWire • 03/26/21
Vir Biotechnology, Inc. (VIR) Surges 32.1%: Is This an Indication of Further Gains?Zacks Investment Research • 03/12/21
Vir Biotechnology spikes 36% after it says its COVID-19 treatment reduced hospitalizations and deaths in high-risk patientsBusiness Insider • 03/11/21
Vir Stock Catapults After Its GSK-Partnered Covid Drug Succeeds In New TestInvestors Business Daily • 03/11/21
Vir/GSK's COVID-19 Antibody Therapy Cuts Hospitalization, Deaths by 85%, Seeks FDA Emergency Use NodBenzinga • 03/11/21
Vir Biotechnology and GSK Announce VIR-7831 Reduces Hospitalization and Risk of Death in Early Treatment of Adults with COVID-19GlobeNewsWire • 03/11/21
Vir Biotechnology and GlaxoSmithKline Expand Their COVID Partnership to FluThe Motley Fool • 03/05/21
Are Options Traders Betting on a Big Move in Vir Biotechnology (VIR) Stock?Zacks Investment Research • 03/04/21
Vir Biotechnology Shares Are Trading Lower As COVID-19 Study VIR-7831 Arm To Stop EnrollmentBenzinga • 03/03/21
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial ResultsGlobeNewsWire • 02/25/21